Literature DB >> 21959975

Lipopolysaccharide upregulates the expression of corticotropin-releasing hormone via MAP kinase pathway in rat peritoneal macrophages.

Wuchao Wang1, Xiuzhu Zhang, Lie Yang, Dawei Liu, Guodong Liu, Jihong Zhou.   

Abstract

The stress neuropeptide, corticotropin-releasing hormone (CRH) is expressed in peripheral tissues and inflammatory sites and is implicated in the modulation of the inflammatory response in a paracrine/ autocrine manner. However, the mechanisms by which CRH expression is regulated in peripheral immune cells are unclear. In this article, we address this question by employing primary rat peritoneal macrophages treated with lipopolysaccharide (LPS). Our results showed that CRH could be detected at the mRNA and protein levels in normal peritoneal macrophages and the levels increased significantly and reached a peak at 4 h after stimulation with 100 ng/ml LPS. Furthermore, LPS-induced CRH expression was inhibited by pretreatment with PD98059, a specific MAP kinase inhibitor, in a dose-dependent fashion in which the mRNA and protein levels of CRH was decreased by 90% and 95%, respectively. In addition, pretreatment with 50 μM SB203580, a p38 MAPK inhibitor, led to the decrease of CRH mRNA level by about 41%. Altogether, these results demonstrate that LPS significantly upregulates CRH expression through MAP kinase signaling pathway in rat peritoneal macrophages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959975     DOI: 10.1007/s11010-011-1080-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

Review 1.  The role of corticotropin-releasing hormone in neuroendocrine-immune interactions.

Authors:  E L Webster; I J Elenkov; G P Chrousos
Journal:  Mol Psychiatry       Date:  1997-09       Impact factor: 15.992

2.  CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes.

Authors:  Blazej Zbytek; Andrzej T Slominski
Journal:  J Invest Dermatol       Date:  2006-10-19       Impact factor: 8.551

Review 3.  Conversation galante: how the immune and the neuroendocrine systems talk to each other.

Authors:  Gabriele Di Comite; Maria Grazia Sabbadini; Angelo Corti; Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  Autoimmun Rev       Date:  2007-03-28       Impact factor: 9.754

Review 4.  Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides.

Authors:  Graham C Boorse; Robert J Denver
Journal:  Gen Comp Endocrinol       Date:  2006-01-18       Impact factor: 2.822

5.  Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis.

Authors:  Christina Benou; Yue Wang; Jaime Imitola; Lilian VanVlerken; Christina Chandras; Katia P Karalis; Samia J Khoury
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

Review 6.  Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors.

Authors:  A Slominski; J Wortsman; A Pisarchik; B Zbytek; E A Linton; J E Mazurkiewicz; E T Wei
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

Review 7.  Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress.

Authors:  A Slominski; J Wortsman; T Luger; R Paus; S Solomon
Journal:  Physiol Rev       Date:  2000-07       Impact factor: 37.312

8.  Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 alpha corticotropin-releasing hormone receptor.

Authors:  A N McEvoy; B Bresnihan; O FitzGerald; E P Murphy
Journal:  Arthritis Rheum       Date:  2001-08

9.  Inhibition of corticotropin releasing hormone type-1 receptor translation by an upstream AUG triplet in the 5' untranslated region.

Authors:  G Xu; C Rabadan-Diehl; M Nikodemova; P Wynn; J Spiess; G Aguilera
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

10.  Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo.

Authors:  K Karalis; H Sano; J Redwine; S Listwak; R L Wilder; G P Chrousos
Journal:  Science       Date:  1991-10-18       Impact factor: 47.728

View more
  5 in total

Review 1.  p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

Authors:  Audreesh Banerjee; Cynthia Koziol-White; Reynold Panettieri
Journal:  Curr Opin Pharmacol       Date:  2012-02-24       Impact factor: 5.547

2.  Corticotropin-releasing Factor Changes the Phenotype and Function of Dendritic Cells in Mouse Mesenteric Lymph Nodes.

Authors:  Li Meng; Zhang Lu; Wang Xiaoteng; Hu Yue; Lu Bin; Meng Lina; Chen Zhe
Journal:  J Neurogastroenterol Motil       Date:  2015-10-01       Impact factor: 4.924

3.  Corticotropin-releasing hormone improves survival in pneumococcal pneumonia by reducing pulmonary inflammation.

Authors:  Brittney Burnley; Harlan P Jones
Journal:  Physiol Rep       Date:  2017-01

4.  Hypothalamic neurohormones and immune responses.

Authors:  J Luis Quintanar; Irene Guzmán-Soto
Journal:  Front Integr Neurosci       Date:  2013-08-13

Review 5.  Progress in the mechanism and targeted drug therapy for COPD.

Authors:  Cuixue Wang; Jiedong Zhou; Jinquan Wang; Shujing Li; Atsushi Fukunaga; Junji Yodoi; Hai Tian
Journal:  Signal Transduct Target Ther       Date:  2020-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.